ZyVersa Therapeutics(ZVSA) - 2024 Q3 - Quarterly Results

Exhibit 99.1 ZyVersa Therapeutics Reports Third Quarter, 2024 Financial Results and Provides Business Update KEY BUSINESS HIGHLIGHTS ● Phase 2a clinical trial for Cholesterol Efflux MediatorVAR 200 in patients with diabetic kidney disease expected to begin Q1- 2025. ● New Obesity, Metabolic & Inflammatory Disease Scientific Advisory Board (SAB) was formed in October 2024 to support development of Inflammasome ASC Inhibitor IC 100 for obesity with metabolic complications. ● Two obesity proof-of-concept studi ...